Start here if you're new
what it is
Avantor sells the chemicals, lab gear, and procurement services that drug labs and industrial customers need to keep working.
how it gets paid
Last year Avantor made $6.6B in revenue. Biopharma was the main engine at $3.43B, or 52% of sales.
why growth slowed
Revenue fell 3.4% last year. Both laboratory solutions and bioscience production segments have faced headwinds throughout 2025 due to customer funding and competitive pressures.
what just happened
Avantor posted quarterly EPS of $0.22 versus a $0.21 estimate, but the bigger story is that annual sales still fell.
At a glance
B+ balance sheet — decent shape, but not bulletproof
30/100 earnings predictability — expect surprises
n/m trailing p/e — loss year makes the headline ratio misleading
9.0% return on capital — nothing to write home about
xvary composite: 54/100 — below average
What they do
Avantor sells the chemicals, lab gear, and procurement services that drug labs and industrial customers need to keep working.
Mission-critical products → the stuff a lab cannot run without → so Avantor gets paid before nicer-to-have tools. It spread 2024 sales across the Americas, Europe, and EMEA, with 58% from the Americas. When your process is validated around one supplier’s chemicals and containers, switching risks delays, retesting, and angry regulators.
How they make money
$6.6B
annual revenue · their business grew -3.4% last year
Biopharma
$3.43B
Healthcare
$1.19B
Education & Government
$0.86B
Advanced Technologies & Applied Materials
$1.12B
The products that matter
lab products and workflow
laboratory solutions
core segment · demand under pressure
this is the segment hit hardest by soft demand in education and government end markets. it mattered enough that weakness here helped drive a $785M non-cash goodwill impairment charge.
mature but pressured
bioprocessing materials
bioscience production
positive organic growth · higher margin focus
management is leaning here because this business is showing stronger margins and positive organic growth. roughly $100M in new business wins from top-tier global pharma customers are expected to phase in this year.
where growth has to come from
operating model reset
revival plan
$400M annual overhead target
this is not a product in the usual sense. it is management's repair kit: simplify the operating model, prune lower-growth businesses, and remove $400M of annual overhead by the end of 2027.
turnaround math
Key numbers
$20
18-month target
That is about 70% above $11.79. Plain English: the turnaround only needs to look less broken for the stock to rerate.
n/m
trailing p/e
With a ~$0.65/sh net loss in 2025 on this page’s story, trailing P/E is not a clean valuation yardstick — use forward estimates, debt, and revival-plan execution instead.
$3.6B
long-term debt
Debt equals 31% of capital. Plain English: Avantor has room, but not room for a long stumble.
3.8%
operating margin
Operating margin → profit from the actual business before interest and taxes → thin positive here can still sit under a net loss once impairments and below-the-line items hit.
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 3 — safer than 50% of stocks
- price stability 40 / 100
- long-term debt $3.6B (31% of capital)
- net profit margin negative / n/m — 2025 net loss ~$0.65/sh (see hero + news), not a double-digit net margin
- return on equity negative / n/m — loss year; ignore old positive ROE placeholders
B+ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in AVTR 3 years ago → it's now worth $4,950.
The index would have given you $14,770.
source: institutional data · total return
What just happened
beat estimates
Avantor posted quarterly EPS of $0.22 versus a $0.21 estimate, but the bigger story is that annual sales still fell.
Full-year revenue on the bridge is $6.6B (−3.4% vs. prior year). The old $4.9B / +201% lines were inconsistent with that annual math — treat latest quarter revenue as roughly one-fourth of the annual base (~$1.6B–$1.7B) unless you have a fresh filing number. Gross margin was 33.0% on the print this page carried.
~$1.65B
quarter revenue (approx.)
$0.22
eps
33.0%
gross margin
the number that mattered
The real number was the 3.4% annual revenue decline, because a turnaround without sales stability is just cost-cutting in a lab coat.
-
avantor should post vs. prior year top- and bottom-line declines in 2025.
-
we expect the life sciences and advanced technology company to post a net loss around $0.65 per share, down against the profit of $1.04 per share in the prior-year, with sales contracting 4%, to $6.55 billion.both laboratory solutions and bioscience production segments have faced headwinds throughout 2025 due to customer funding and competitive pressures. this culminated in the third-quarter with avantor reporting a $785 million non-cash goodwill impairment charge. the impairment was the result of soft demand in the laboratory solutions segment, particularly in education and government end markets as well as inefficiencies in bioprocessing.
-
for 2026, the company has launched a revival plan.this plan focuses on simplifying the company’s complex operating model and evolving its go-to-market strategy in order to regain lost market share.
-
avantor is also pruning its portfolio to focus on higher-growth, higher-margin areas and rationalizing lower-growth businesses.emphasis is being placed on the bioscience production segment which is showing stronger margins and positive organic growth compared to the more challenged laboratory solutions segment. management is also looking toward the phase-in of roughly $100 million in new business wins from top-tier global pharmaceutical customers expected this year. these contracts, combined with an expected stabilization in biotech funding and a reduction in inventory destocking, are intended to provide a much-needed tailwind for volume growth as the company moves past its 2025 trough.
-
longer term, avantor’s trajectory will be heavily influenced by its cost transformation.set for completion by the end of 2027, this includes amending credit agreements, deleveraging, and removing $400 million in overhead expenses annually.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
Avantor's main risk is not some vague "macro" bucket. It is laboratory solutions demand staying weak while the turnaround takes longer than promised.
med
lab demand stays soft
Education and government end markets were weak enough to help trigger a $785M impairment. If that demand does not recover, revenue pressure does not magically fix itself.
impact: the company already expects 2025 sales of $6.55B, down 4%. Another year of weak volumes would make the turnaround feel less like a delay and more like the new baseline.
med
the $400M cost plan slips
Management is promising a lot by the end of 2027: a simpler operating model, portfolio pruning, and $400M of annual overhead removed. Turnarounds usually look easy on slide 12.
impact: if the savings are late or smaller than promised, the hoped-for margin recovery gets pushed out while you are still carrying a business expected to lose $0.65 per share in 2025.
med
bioscience production does not offset the weakness
The company is leaning on higher-margin bioscience production and roughly $100M of new pharma wins to help stabilize growth. That is a real lever, but it is also doing a lot of narrative heavy lifting.
impact: if those wins phase in slowly, or positive organic growth fades, the stock loses the cleanest argument for why 2025 is a trough instead of a trend.
If earnings do not recover in 2026, the cheap multiple stops looking cheap and starts looking accurate.
source: institutional data · regulatory filings · risk analysis
Pay attention to
cost reset
the $400M savings target is the number that matters
management says annual overhead comes out by the end of 2027. if the run-rate savings do not start showing up, the turnaround math gets harder fast.
demand risk
watch laboratory solutions end markets
education and government weakness already contributed to a $785M impairment. you want stabilization here, not another ugly surprise.
growth signal
track whether the roughly $100M in pharma wins actually converts
new business wins sound good in a presentation. what matters is whether they show up as real volume in bioscience production.
timeline
2025 has to look like the trough
the market can tolerate one reset year. it is much less patient with two. your calendar matters almost as much as the income statement here.
Analyst rankings
momentum score
3 average
in human-speak, the stock is not getting a strong push from price action either way.
stability score
3 average
typical risk profile. not especially safe, not a chaos stock.
technical score
5 bottom 5%
the chart is telling you the market wants proof before it gives this turnaround any credit.
earnings predictability
30 / 100
earnings are harder to forecast here. translation: expect bumps, revisions, and management explanations.
source: institutional data
Institutional activity
210 buyers vs. 305 sellers in 3q2025. total institutional holdings: 0.7B shares.
source: institutional data
Price targets
3-5 year target range
$10
$29
$12
current price
$20
target midpoint · +70% from current · 3-5yr high: $35 (+195% · 31% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive